Proteome Sciences PLC AGM Statement and Result of AGM (1887C)
24 June 2016 - 12:30PM
UK Regulatory
TIDMPRM
RNS Number : 1887C
Proteome Sciences PLC
24 June 2016
PRESS RELEASE
Proteome Sciences plc
("Company" or the "Group")
AGM Statement and Result of AGM
24 June 2016
At the AGM held earlier today it was announced that revenues
from the core biomarker services activities remained buoyant in the
first half with a strong order book, including repeat business, and
a developing pipeline. TMT revenue growth has continued into 2016
and TMT was highly visible at the recent meeting of the American
Society for Mass Spectrometry. The growing recognition of tau as a
therapeutic target in Alzheimer's disease should increase interest
in new treatments which could favourably affect our compounds
targeting CK1d in the tau pathway. We are confident that the
business remains on track in 2016 to deliver a significant increase
in revenues.
At the AGM all resolutions were duly passed.
- Ends -
For further information please contact:
Proteome Sciences plc
Dr. Jeremy Haigh, Chief Executive
Officer
Dr. Ian Pike, Chief Operating Tel: +44 (0)1932 865065
Officer
Geoff Ellis, Finance Director
finnCap Limited (Nominated
Adviser/Broker) Tel : +44 (0)20 7220
Geoff Nash/James Thompson 0500
Public Relations
IKON Associates Email: adrian@ikonassociates.com
Adrian Shaw Tel: +44 (0)1483 271291
Mobile +44(0)7979 900733
Notes for editors:
About Proteome Sciences plc (www.proteomics.com)
With its HQ in Cobham, UK and laboratory facilities in London
and Frankfurt, Proteome Sciences is a global leader in applied
proteomics offering high sensitivity, proprietary technologies and
workflows in cell signalling pathways (SysQuant(R),
TMTcalibrator(TM)) and in protein biomarker discovery, validation
and assay development.
PS Biomarker Services(R) provides proteomics outsourcing
services and proprietary biomarker assays from its ISO 9001: 2008
facility in Frankfurt, Germany to pharmaceutical, biotechnology,
diagnostics companies and academia.
Proteome Sciences' research has discovered a large number of
novel protein biomarkers in key human diseases with a focus mainly
in neurological/neurodegenerative conditions and in cancer. It has
patented blood biomarkers in Alzheimer's disease, stroke, brain
damage and cancers for diagnostic and treatment applications that
are available for licenses.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGPGUBWQUPQUMC
(END) Dow Jones Newswires
June 24, 2016 07:30 ET (11:30 GMT)